Completed PHASE2 INTERVENTIONAL 2-arm NCT04013672

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Sponsor: David Peereboom

Interventions Montanide ISA 51 Pembrolizumab Sargramostim SurVaxM

Updated 10 times since 2019 Last updated: Aug 9, 2024 Started: Mar 19, 2020 Primary completion: Aug 16, 2021 Completion: Feb 16, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04013672, this PHASE2 trial focuses on Recurrent Glioblastoma and remains completed. Sponsored by David Peereboom, it has been updated 10 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Sep 2021 — Sep 2022 [monthly]

Active Not Recruiting PHASE2
Apr 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 5 earlier versions

Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE2
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Apr 2020 — Sep 2020 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2020 — Apr 2020 [monthly]

Not Yet Recruiting PHASE2
Aug 2019 — Jan 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

David Peereboom

Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States